Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Oral Proteins And Peptides Market Size Forecast: How Big Could The Market Get By 2030?
The oral proteins and peptides market size has seen significant expansion in recent years. This market is projected to increase from $1.56 billion in 2025 to $1.91 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 22.5%. The historical growth experienced by this market can be attributed to factors such as limited oral bioavailability of proteins and peptides, reliance on injectable formulations, growing prevalence of diabetes and gastrointestinal disorders, increasing research in peptide therapeutics, and regulatory approvals for early oral peptide drugs.
The oral proteins and peptides market is anticipated to experience substantial growth in the upcoming years. It is projected to expand to $4.26 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 22.2%. This growth over the forecast period is fueled by the advancement of innovative delivery technologies for oral proteins, the expansion of chronic disease management initiatives, the increasing embrace of personalized and combination therapies, higher healthcare spending on metabolic and hormonal disorders, and the integration of digital tools for adherence and monitoring. Significant trends for this period encompass the rising adoption of oral insulin and other therapeutic peptides, the evolution of personalized medicine and targeted oral protein treatments, an increased focus on therapies for gastrointestinal disorders, the broader availability of oral protein formulations for diabetes and metabolic conditions, and innovations in long-acting and combination oral protein products.
Get A Free Sample Report With In-Depth Market Insights:
Oral Proteins And Peptides Market Growth Catalysts And Demand Drivers
The expansion of the biopharmaceutical sector is projected to drive the future development of the oral proteins and peptides market. This industry segment, part of the wider pharmaceutical field, is dedicated to the creation, manufacture, and sale of medications originating from biological sources. This sector’s expansion stems from progress in biotechnology, a rising need for personalized treatments, a greater incidence of chronic illnesses, and increased spending on research and development initiatives. Within biopharmaceuticals, oral proteins and peptides present an opportunity for administering therapies without invasion, thereby improving patient adherence and lessening the requirement for injections. They are capable of targeting particular ailments, exhibiting better stability and uptake within the digestive system. As an illustration, in October 2025, data from the Bioscience and Health Technology Sector, a source of UK government statistics, indicated that during 2023/2024, the UK life sciences industry contained 6,170 businesses spanning 7,320 companies. These operations provided employment for 359,600 individuals and achieved a turnover of £146.9 ($169.69) billion. Consequently, the expanding biopharmaceutical industry is serving as a catalyst for the growth of the oral proteins and peptides market.
Oral Proteins And Peptides Market Breakdown By Product Type And Application
The oral proteins and peptides market covered in this report is segmented –
1) By Drug Type: Linaclotide, Calcitonin, Insulin, Plecanatide, Octreotide
2) By Biological Target: Guanylate Cyclase-C (GC-C), Insulin Receptor, Other Biological Targets
3) By Mechanism Of Action: Receptor Stimulation, Substrate Degradation, Other Mechanisms Of Action
4) By Application: Gastrointestinal Disorders, Bone Disease, Neurological Disorders, Diabetes, Metabolic Disorders, Hormonal Disorder, Cancer
Subsegments:
1) By Linaclotide: Indications For Irritable Bowel Syndrome (IBS), Indications For Chronic Idiopathic Constipation (CIC)
2) By Calcitonin: Calcitonin-Salmon, Synthetic Calcitonin, Calcitonin for Osteoporosis Treatment
3) By Insulin: Long-Acting Insulin, Combination Insulin Products, Oral Insulin Formulations
4) By Plecanatide: Indications For Chronic Idiopathic Constipation (CIC), Indications For Irritable Bowel Syndrome With Constipation (IBS-C)
5) By Octreotide: Long-Acting Octreotide Formulations, Short-Acting Octreotide Formulations, Indications For Acromegaly And Neuroendocrine Tumors
Oral Proteins And Peptides Market Trends Shaping Long-Term Demand
Major companies operating in the oral proteins and peptides market are focusing on developing innovative formulation technologies to enhance peptide stability, permeability, and bioavailability in oral dosage forms. These advancements aim to overcome traditional challenges such as enzymatic degradation and poor absorption in the gastrointestinal tract. For instance, in August 2025, BioMed X, a Germany-based biomedical research institute, launched a new collaboration with Novo Nordisk, a Denmark-based pharmaceutical company, to accelerate the development of next-generation oral peptide delivery technologies. The partnership will explore novel molecular strategies and delivery mechanisms to enable safe, effective, and patient-friendly oral peptide therapeutics. By integrating BioMed X’s early-stage research capabilities with Novo Nordisk’s expertise in peptide-based medicines, the collaboration aims to advance breakthrough oral drug delivery solutions and expand the therapeutic potential of peptide medicines across metabolic and chronic diseases.
Oral Proteins And Peptides Market Company Landscape And Competitive Strategy
Major companies operating in the oral proteins and peptides market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Eli Lilly and Company, Novo Nordisk A/S, Ipsen S.A., Biocon Limited, Xeris Pharmaceuticals Inc., Adocia S.A., Zealand Pharma A/S, Diabetology Ltd., Oramed Pharmaceuticals Inc., Palatin Technologies Inc., Entera Bio Ltd.
View The Full Oral Proteins And Peptides Market Report:
Oral Proteins And Peptides Market Global Footprint: Which Region Leads The Industry?
North America was the largest region in the oral proteins and peptides market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oral proteins and peptides market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model